BridgeMD
New treatment option for Intrahepatic Cholangiocarcinoma
Official title Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov ID: NCT04078230
What this study is testing
- What it's testing
- Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Patients \>18 years of age and ≤80 years of age;
- Preoperative imaging and laboratory examination for intrahepatic cholangiocarcinoma, intraoperative frozen and postoperative pathology confirmed as...
- No obvious lymph node metastasis in preoperative imaging; or negative intraoperative lymph node biopsy
- Liver function Child-Turcotte-Pugh score A-B grade;
- Residual liver volume \>30%; can tolerate radical hepatectomy
You likely can't join if
- The patient has obvious heart, lung, brain and kidney dysfunction that affects the treatment of intrahepatic cholangiocarcinoma;
- The patient has a history of other malignant tumors;
- Liver function Child-Turcotte-Pugh score C;
- The investigator determined that it was not suitable for the study.
See the full eligibility criteria
- Patients \>18 years of age and ≤80 years of age;
- Preoperative imaging and laboratory examination for intrahepatic cholangiocarcinoma, intraoperative frozen and postoperative pathology confirmed as intrahepatic cholangiocarcinoma; preoperative imaging assessment is...
- No obvious lymph node metastasis in preoperative imaging; or negative intraoperative lymph node biopsy
- Liver function Child-Turcotte-Pugh score A-B grade;
- Residual liver volume \>30%; can tolerate radical hepatectomy
- The patient has autonomy, understands and voluntarily signs the written informed consent and is able to complete the follow-up plan;
- Sign the written informed consent form prior to the test screening.
- The patient has obvious heart, lung, brain and kidney dysfunction that affects the treatment of intrahepatic cholangiocarcinoma;
- The patient has a history of other malignant tumors;
- Liver function Child-Turcotte-Pugh score C;
- The investigator determined that it was not suitable for the study.
The study team makes the final eligibility decision.
Where it's taking place
- Baltimore, Maryland, United States
- Beijing, Beijing Municipality, China
- Guangzhou, Guangdong, China
- Changsha, Hunan, China
- Hohhot, Inner Mongolia, China
- Shanghai, Shanghai Municipality, China
- Xi’an, Shanxi, China
- Chengdu, Sichuan, China
- Hanzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Baltimore, Maryland, United States; Beijing, Beijing Municipality, China; Guangzhou, Guangdong, China; Changsha, Hunan, China; Hohhot, Inner Mongolia, China; Shanghai, Shanghai Municipality, China and 3 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.